Thrombocytopenia in Patients With Myelodysplastic Syndromes

Seminars in Hematology

Volumn 47, Issue 3, 2010, Pages 274-280

  Bryan, Jeffrey ^a   Jabbour, Elias ^a   Prescott, Hillary ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYCLOSPORIN; ELTROMBOPAG; IMMUNOMODULATING AGENT; LENALIDOMIDE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 6; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; RECOMBINANT THROMBOPOIETIN AGONIST; ROMIPLOSTIM; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR AGONIST; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOIMMUNIZATION; ANAPHYLAXIS; ANEMIA; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; BLEEDING; CHILL; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CROSS REACTION; DRUG APPROVAL; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EYE INFECTION; FATIGUE; FLU LIKE SYNDROME; FLUID RETENTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; LUNG EDEMA; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PAPILLEDEMA; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT;

HUMANS; MYELODYSPLASTIC SYNDROMES; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 77953907494     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.02.006     Document Type: Article

References (48)

1. Aul C., Giagounidis A., Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 2001, 73:405-410.
2. Greenberg P.L., Young N.S., Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2002, 136-161.
3. Hofmann W.K., Koeffler H.P. Myelodysplastic syndrome. Annu Rev Med 2005, 56:1-16.
4. Kouides P.A., Bennett J.M. Understanding the myelodysplastic syndrome. Oncologist 1997, 2:389-401.
5. Bowen D., Culligan D., Jowitt S., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003, 120:187-200.
6. Kantarjian H., Giles F., List A., et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007, 109:1705-1714.
7. Doll D.C., List A.F. Myelodysplastic syndromes. West J Med 1989, 151:161-167.
8. Alessandrino E.P., Amadori S., Barosi G., et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002, 87:1286-1306.
9. Mittelman M., Sokolover N., Zeidman A., Redlich O., Cohen A., Fradin Z. Platelet aggregation and its clinical significance in the myelodysplastic syndromes. Leuk Res 1999, 23(suppl 1):s24.
10. Kezuka T., Usui N., Suzuki E., Wakasugi K., Usui M. Ocular complications in myelodysplastic syndromes as preleukemic disorders. Jpn J Ophthalmol 2005, 49:377-383.
11. Wattel E., Cambier N., Caulier M.T., Sautiere D., Bauters F., Fenaux P. Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol 1994, 87:205-208.
12. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
13. Powell B.L., Capizzi R.L., Jackson D.V., et al. Low dose Ara-C for patients with myelodysplastic syndromes. Leukemia 1988, 2:153-156.
14. Rosenfeld C.S., Zeigler Z.R., Shadduck R.K., Nilsson B. Phase II study of roquinimex in myelodysplastic syndrome. Am J Clin Oncol 1997, 20:189-192.
15. Picozzi V.J., Swanson G.F., Morgan R., Hecht F., Greenberg P.L. 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol 1986, 4:589-595.
16. Wu H.H., Talpaz M., Champlin R.E., Pilat S.R., Kurzrock R. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer 2003, 98:2410-2419.
17. Lee S.T., Jang J.H., Suh H.C., Hahn J.S., Ko Y.W., Min Y.H. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome. Am J Hematol 2001, 68:237-245.
18. Gupta P., LeRoy S.C., Luikart S.D., Bateman A., Morrison V.A. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 1999, 23:953-959.
19. Konstantopoulos K., Lauren L., Hast R., Reizenstein P. Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome. Anticancer Res 1989, 9:893-896.
20. Sullivan M.T., Wallace E.L. Blood collection and transfusion in the United States in 1999. Transfusion 2005, 45:141-148.
21. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol 2000, 37:3-10.
22. Besa E.C., Woermann U. Myelodysplastic syndrome. eMedicine http://www.emedicine.com/med/topic2695.htm.
23. Platelet transfusion therapy. JAMA 1987, 257:1777-1780. Consensus conference.
24. Sepulveda J.L. Alloimmunization from transfusions http://emedicine.medscape.com.
25. Gelb A.B., Leavitt A.D. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion 1997, 37:624-630.
26. Meehan K.R., Matias C.O., Rathore S.S., et al. Platelet transfusions: utilization and associated costs in a tertiary care hospital. Am J Hematol 2000, 64:251-256.
27. Kuehnert M.J., Roth V.R., Haley N.R., et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001, 41:1493-1499.
28. Wolkers W.F., Walker N.J., Tablin F., Crowe J.H. Human platelets loaded with trehalose survive freeze-drying. Cryobiology 2001, 42:79-87.
29. Silverman L.R., McKenzie D.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
30. Kantarjian H., Issa J.-P.J., Rosenfeld C., et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 2006, 106:1794-1803.
31. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
32. Cermak J., Belickova M., Michalova K. Combined immunosuppressive treatment in patients with early myelodysplasia. Haematologica 2005, 90(Suppl 2):357.
33. Deeg H.J., Jiang P.Y., Holmberg L.A., Scott B., Petersdorf E.W., Appelbaum F.R. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res 2004, 28:1177-1180.
34. Tsimberidou A.M., Giles F.J., Khouri I., et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M.D. Anderson Cancer Center experience. Ann Oncol 2005, 16:139-145.
35. Kurzrock R., Cortes J., Thomas D.A., Jeha S., Pilat S., Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001, 19:4165-4172.
36. Neumega (oprelvekin) prescribing information 2006, Wyeth Pharmaceuticals, Philadelphia, PA.
37. Gordon M.S., Nemunaitis J., Hoffman R., et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995, 85:3066-3076.
38. Li J., Yang C., Xia Y., Bertino A., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
39. Urabe A., Komatsu N., Okomoto T., et al. Effects of pegylated recombinant human megakaryocyte growth and developement factor on haematopoiesis in patients with aplastic anemia and myelodysplastic syndrome. Exp Hematol 2001, 29:112.
40. Basser R.L., O'Flaherty E., Green M., et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002, 99:2599-2602.
41. Vadhan-Raj S., Murray L.J., Bueso-Ramos C., et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997, 126:673-681.
42. Vadhan-Raj S., Verschraegen C.F., Bueso-Ramos C., et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000, 132:364-368.
43. Sekeres M., Kantarjian H., Fenaux P., et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS) [abstract]. J. Clin. Oncol 2009, 27(15S):7009.
44. Kantarjian H., Pierre Fenaux P., Sekeres M.A., et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010, 28:437-444.
45. Kantarjian H., Giles F., Greenberg P., et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine [abstract]. ASH Annual Meeting Abstracts 2008, 112:224.
46. Greenberg P.L., Garcia-Manero G., Moore M.R., et al. Efficacy and safety of romiplostim in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine [abstract]. ASH Annual Meeting Abstracts 2009, 114:1769.
47. Lyons R.M., Larson R.A., Kosmo M.A., et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving Lenalidomide [abstract]. ASH Annual Meeting Abstracts 2009, 114:1770.
48. Will B., Kawahara M., Luciano J.P., et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009, 114(18):3899-3908.